X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (24) 24
humans (23) 23
index medicus (23) 23
female (12) 12
male (12) 12
cancer (10) 10
mutation (10) 10
lung cancer (9) 9
lung neoplasms - drug therapy (9) 9
animals (8) 8
docetaxel (8) 8
middle aged (8) 8
aged (7) 7
basic electric elements (7) 7
cell line, tumor (7) 7
electricity (7) 7
lung neoplasms - genetics (7) 7
lung neoplasms - pathology (7) 7
measuring (7) 7
measuring electric variables (7) 7
measuring magnetic variables (7) 7
mice (7) 7
non-small cell lung cancer (7) 7
physics (7) 7
processes or means, e.g. batteries, for the direct conversionof chemical into electrical energy (7) 7
protein kinase inhibitors - pharmacology (7) 7
testing (7) 7
antineoplastic agents - therapeutic use (6) 6
carcinoma, non-small-cell lung - drug therapy (6) 6
carcinoma, non-small-cell lung - genetics (6) 6
cell proliferation - drug effects (6) 6
lung cancer, non-small cell (6) 6
nivolumab (6) 6
non–small cell lung cancer (6) 6
patients (6) 6
receptor, epidermal growth factor - genetics (6) 6
adult (5) 5
apoptosis - drug effects (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
chemotherapy (5) 5
epidermal growth factor (5) 5
resistance (5) 5
xenograft model antitumor assays (5) 5
analysis (4) 4
antineoplastic agents - pharmacology (4) 4
breast cancer (4) 4
care and treatment (4) 4
chemistry, multidisciplinary (4) 4
drug combinations (4) 4
epidermal growth factor receptors (4) 4
erbb-2 protein (4) 4
gefitinib (4) 4
gene amplification (4) 4
kinases (4) 4
molecular targeted therapy (4) 4
mutations (4) 4
respiratory system (4) 4
survival (4) 4
treatment outcome (4) 4
adenocarcinoma (3) 3
adenocarcinoma - drug therapy (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antitumor activity (3) 3
apoptosis (3) 3
breast neoplasms - drug therapy (3) 3
cancer therapies (3) 3
carcinoma, squamous cell - pathology (3) 3
dose-response relationship, drug (3) 3
drug resistance, neoplasm (3) 3
drug resistance, neoplasm - drug effects (3) 3
drug resistance, neoplasm - genetics (3) 3
drug-resistance (3) 3
epidermal growth factor receptor (3) 3
expression (3) 3
genetic aspects (3) 3
growth-factor receptor (3) 3
her2 (3) 3
inhibitor (3) 3
inhibitors (3) 3
insertion (3) 3
liver (3) 3
lung-cancer (3) 3
medical research (3) 3
metastasis (3) 3
mice, nude (3) 3
original (3) 3
quinazolines - therapeutic use (3) 3
receptor, epidermal growth factor - antagonists & inhibitors (3) 3
receptor, epidermal growth factor - metabolism (3) 3
receptor, erbb-2 - genetics (3) 3
receptor, fibroblast growth factor, type 2 - genetics (3) 3
respiratory tract diseases (3) 3
sensitivity (3) 3
signal transduction - drug effects (3) 3
trastuzumab (3) 3
tumors (3) 3
adenocarcinoma - pathology (2) 2
adenocarcinoma of lung (2) 2
afatinib (2) 2
agriculture (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1667 - 1676
Fibroblast growth factor receptor ( FGFR ) gene alterations are relatively frequent in lung squamous cell carcinoma ( LSCC ) and are a potential targets for... 
nintedanib | Copy number gain | FGFR | lung squamous cell cancer | next‐generation sequencing | next-generation sequencing | FGFR1 | CONTROLLED-TRIAL | BLADDER-CANCER | BIBF 1120 | AMPLIFICATION | ONCOLOGY | RANDOMIZED PHASE-II | GASTRIC-CANCER | TRIPLE ANGIOKINASE INHIBITOR | THERAPEUTIC TARGET | DOUBLE-BLIND | MUTATIONS | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Mutant Proteins - genetics | Neoplasm Recurrence, Local | Lung Neoplasms - pathology | DNA Copy Number Variations - genetics | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Xenograft Model Antitumor Assays | Animals | Carcinoma, Squamous Cell - drug therapy | Survival Analysis | Female | Indoles - pharmacology | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Receptor, Fibroblast Growth Factor, Type 2 - genetics | RNA sequencing | Squamous cell carcinoma | Relapse | Analysis | Genes | Genetic research | Genetic aspects | Nucleotide sequencing | Lung cancer, Non-small cell | DNA sequencing | Cancer | Diseases | Fibroblast growth factor | Copy number | Lung cancer | Clinical trials | Values | Kinases | Signal transduction | Cell growth | Surgery | Fibroblast growth factor receptor 4 | Fibroblasts | Fibroblast growth factor receptor 1 | Vascular endothelial growth factor | Fibroblast growth factor receptor 2 | Medical research | Immunoglobulins | Small cell lung carcinoma | Research funding | Committees | Extracellular signal-regulated kinase | Lung carcinoma | Patients | Gene amplification | Medical prognosis | Cell lines | Antitumor activity | Mutation | University faculty | Laboratory animals | Esophageal cancer | Pharmaceuticals | Fibroblast growth factor receptors | Tumors | Index Medicus | Original
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 11/2014, Volume 111, Issue 45, pp. E4869 - E4877
The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation.... 
Structure-based drug design | Drug discovery | Cancer drug resistance | Kinase inhibitor | structure-based drug design | WILD-TYPE | MULTIDISCIPLINARY SCIENCES | BCR-ABL | GROWTH-FACTOR RECEPTORS | DRUG-RESISTANCE | kinase inhibitor | LUNG-CANCER | GENE FUSIONS | cancer drug resistance | SELECTIVE INHIBITOR | drug discovery | THERAPEUTIC TARGET | FACTOR RECEPTOR 4 | REGULATES PROLIFERATION | Receptor, Fibroblast Growth Factor, Type 4 - chemistry | Receptor, Epidermal Growth Factor - genetics | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Receptor, Fibroblast Growth Factor, Type 2 - chemistry | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Crystallography, X-Ray | Structure-Activity Relationship | Mutation, Missense | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Binding Sites | Neoplasms - enzymology | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Receptor, Epidermal Growth Factor - chemistry | Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - chemistry | Neoplasms - pathology | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Amino Acid Substitution | Drug Resistance, Neoplasm - drug effects | Amino acids | T cell receptors | Mutation | Kinases | Binding sites | Adenosine triphosphatase | Index Medicus | Biological Sciences | PNAS Plus
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2015, Volume 21, Issue 17, pp. 4014 - 4021
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2018, Volume 13, Issue 5, pp. e86 - e87
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2712 - 2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | ONCOLOGY | ADENOCARCINOMAS | RESISTANCE | OPEN-LABEL | MUTATIONS | TUMORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Exons | Humans | Middle Aged | Molecular Conformation | Receptor, ErbB-2 - chemistry | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Codon | Adult | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Disease Models, Animal | Lung Neoplasms - genetics | Gene Expression | Models, Molecular | Treatment Outcome | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Binding | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Mutagenesis, Insertional | Protein Kinase Inhibitors - pharmacology | Lung Neoplasms - diagnosis | Amino Acid Substitution | Epidermal growth factor receptors | Lung cancer | Insertion | Drug resistance | Patients | ErbB-2 protein | Mutants | Sensitivity | Covalence | Inhibitors | Mutation | Tumors | Cancer | Index Medicus | human epidermal growth factor receptor 2 | drug resistance | tyrosine kinase inhibitor | exon 20 | Epidermal growth factor receptor
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 06/2015, Volume 106, Issue 6, pp. 734 - 739
We conducted a phase I study of a weekly nab ‐paclitaxel and S‐1 combination therapy in patients with human epidermal growth factor receptor type 2‐negative... 
paclitaxel | S‐1 | phase I study | Combination chemotherapy | nab | metastatic breast cancer | nab-paclitaxel | Phase I study | Metastatic breast cancer | S-1 | SURVIVAL | GUIDELINES | COMBINATION | DOCETAXEL | CHEMOTHERAPY | THERAPY | ONCOLOGY | RECURRENT | ALBUMIN-BOUND PACLITAXEL | ABI-007 | III TRIAL | Drug Administration Schedule | Humans | Middle Aged | Tegafur - adverse effects | Paclitaxel - adverse effects | Albumins - administration & dosage | Paclitaxel - pharmacokinetics | Oxonic Acid - administration & dosage | Breast Neoplasms - drug therapy | Tegafur - pharmacokinetics | Oxonic Acid - adverse effects | Breast Neoplasms - chemistry | Albumins - pharmacokinetics | Albumins - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Adult | Breast Neoplasms - mortality | Female | Aged | Oxonic Acid - pharmacokinetics | Receptor, ErbB-2 - analysis | Paclitaxel - administration & dosage | Drug Combinations | Antimitotic agents | Complications and side effects | Medical research | Care and treatment | Chemotherapy | Epidermal growth factor | Medicine, Experimental | Breast cancer | Metastasis | Antineoplastic agents | Cancer | Toxicity | Cytotoxicity | Peripheral neuropathy | Patients | Cancer therapies | Metastases | Medical prognosis | Paclitaxel | Clinical medicine | Drug dosages | Neutropenia | Pharmaceuticals | Index Medicus | Original
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2017, Volume 35, Issue 4, pp. 529 - 536
Background Nivolumab demonstrates promising efficacy for the treatment of non-small cell lung cancer and other malignancies. The clinical benefit of nivolumab,... 
Medicine & Public Health | Cholangitis | Oncology | Nivolumab monotherapy | Pharmacology/Toxicology | Immune-related adverse event | Programmed death-1 | ANTI-PD-L1 ANTIBODY | MELANOMA | DISEASES | ONCOLOGY | SAFETY | PHARMACOLOGY & PHARMACY | DOCETAXEL | MPDL3280A | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Cholangitis - chemically induced | Liver - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Liver - diagnostic imaging | Aged, 80 and over | Cholangitis - diagnostic imaging | Female | Lung Neoplasms - diagnostic imaging | Aged | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - drug therapy | Cholangitis - pathology | Care and treatment | Research | Diagnosis | Lung cancer, Non-small cell | Risk factors | Biliary tract | Therapy | Alkaline phosphatase | Intravenous administration | g-Glutamyltransferase | Identification methods | Liver | Lung | Lung cancer | Medical services | Parenchyma | Smooth muscle | Lymphocytes T | Metastases | Immunology | Search methods | Etiology | Enzymes | Alanine | Abnormalities | Markers | Non-small cell lung carcinoma | Immunoglobulin G4 | Patients | Bile duct | Hepatocytes | Biopsy | Alanine transaminase | Infiltration | Differentiation | Hypertrophy | Cancer | Bile | Index Medicus
Journal Article
Journal Article
BMC Research Notes, ISSN 1756-0500, 12/2013, Volume 6, Issue 1, pp. 541 - 541
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2018, Volume 13, Issue 1, pp. 97 - 105
Journal Article
Nihon rinsho. Japanese journal of clinical medicine, ISSN 0047-1852, 2012, Volume 70, pp. 336 - 340
Journal Article
Journal Article